Core Viewpoint - The company plans to issue A-shares to specific investors in 2025, which may dilute immediate returns for existing shareholders, but it has proposed measures to mitigate this impact [1][5][9]. Impact on Earnings Per Share - The issuance is expected to increase the total share capital from 44,533.57 million shares to 48,986.93 million shares [2]. - In a scenario where the net profit attributable to shareholders decreases by 10%, the diluted earnings per share (EPS) would drop from 0.24 to 0.18 yuan [2]. - If the net profit remains flat compared to 2024, the diluted EPS would decrease from 0.24 to 0.20 yuan [4]. - In a scenario where the net profit increases by 10%, the diluted EPS would slightly decrease from 0.24 to 0.23 yuan [4]. Necessity and Reasonableness of the Issuance - The issuance aims to supplement working capital to support business growth, especially in the high-investment biopharmaceutical and vaccine sectors [5][6]. - Continuous R&D investment is crucial for maintaining competitive advantages, and the funds will support ongoing innovation [5][6]. - The issuance will help reduce operational and financial risks by improving the company's financial structure and liquidity [6]. Use of Proceeds - All proceeds from the issuance will be used to enhance working capital, accelerating the R&D process and enriching the product pipeline [6][7]. Measures to Mitigate Dilution of Immediate Returns - The company will manage the raised funds strictly according to legal regulations to ensure proper usage [7][8]. - A detailed plan for the use of funds will be implemented to enhance business development and market competitiveness [7]. - The company will improve governance and internal controls to protect investor interests and ensure efficient fund utilization [8]. - A profit distribution policy will be established to optimize returns for investors, with a commitment to cash dividends when conditions allow [8][9]. Commitments from Management - The board of directors and senior management have committed to ensuring the effectiveness of the proposed measures to mitigate dilution [9][10]. - The actual controller and major shareholders have also made commitments to not interfere with the company's management and to protect shareholder interests [10][11].

Group 1 - The company plans to raise a total of no more than 900 million yuan through a private placement of A-shares, with all proceeds intended to supplement working capital after deducting issuance costs [1] - The necessity of the fundraising is highlighted by the company's rapid business expansion, with revenue growth rates of 661.33%, 84.46%, and 33.13% in recent years, indicating a strong demand for operational funds in the high-tech biopharmaceutical and vaccine sectors [1][2] - The company has a significant historical investment in R&D, with expenditures of 973 million yuan, 1.217 billion yuan, and 936 million yuan for the years 2022, 2023, and 2024 respectively, and cumulative losses reaching 3.76 billion yuan as of March 31, 2025 [2] Group 2 - The issuance of new shares is expected to enhance the company's financial strength, reduce the debt-to-asset ratio, and improve liquidity, thereby increasing operational safety and asset fluidity [2][3] - The company has established a modern corporate governance structure and a clear management framework for the use of raised funds, ensuring compliance with relevant laws and regulations [3] - Following the completion of the issuance, both total assets and net assets will increase, further improving the company's financial condition and risk resistance capabilities [4]